Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
Phase 1
1(33.3%)
3Total
Early Phase 1(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07344519Early Phase 1Active Not Recruiting

The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.

Role: lead

NCT07339514Phase 1Active Not Recruiting

A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.

Role: lead

NCT06024265Early Phase 1Completed

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

Role: lead

All 3 trials loaded